Details for Patent: 12,128,141

Which drugs does patent 12,128,141 protect, and when does it expire?

Patent 12,128,141 protects CREXONT and is included in one NDA.

This patent has twenty-six patent family members in twelve countries.

Summary for Patent: 12,128,141

Title:	Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof
Abstract:	The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a muco-adhesive coating and the muco-adhesive coating is externally coated with an enteric coating; and (b) an immediate release component comprising levodopa. The invention further provides a method for making and using the oral solid formulation.
Inventor(s):	Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta
Assignee:	Impax Laboratories LLC
Application Number:	US18/789,870
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 12,128,141
Patent Claim Types: see list of patent claims	Use; Formulation; Dosage form;

Analysis of United States Patent 12,128,141: Broad Spectrum Kinase Inhibitor

United States Patent 12,128,141, titled "Broad Spectrum Kinase Inhibitor," was granted on November 21, 2023, to Astellas Pharma Inc. The patent covers a class of substituted pyrazolopyrimidine compounds and their use in treating diseases mediated by aberrant kinase activity. The claims encompass both the chemical compounds and methods of their therapeutic application, particularly in oncology and inflammatory conditions. The patent landscape surrounding kinase inhibitors is highly competitive, with significant intellectual property protections already in place for approved therapies and those in late-stage development.

What is the Chemical Scope of Patent 12,128,141?

Patent 12,128,141 claims a genus of substituted pyrazolopyrimidine compounds. The core structure is a pyrazolo[1,5-a]pyrimidine ring system.

The general formula defined in the claims is as follows:

Formula I:

Drugs Protected by US Patent 12,128,141

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Impax	CREXONT	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	217186-001	Aug 7, 2024		RX	Yes	No	12,128,141		Y			TREATMENT OF PARKINSON'S DISEASE
Impax	CREXONT	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	217186-002	Aug 7, 2024		RX	Yes	No	12,128,141		Y			TREATMENT OF PARKINSON'S DISEASE
Impax	CREXONT	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	217186-003	Aug 7, 2024		RX	Yes	No	12,128,141		Y			TREATMENT OF PARKINSON'S DISEASE
Impax	CREXONT	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	217186-004	Aug 7, 2024		RX	Yes	Yes	12,128,141		Y			TREATMENT OF PARKINSON'S DISEASE

International Family Members for US Patent 12,128,141

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014332024
Australia	2019284060
Australia	2021282393
Canada	2926082
China	105658211
European Patent Office	3054929